PTC Therapeutics, Inc. officer Mark Elliott Boulding filed a Form 144 notice on November 16, 2026, disclosing a proposed sale of 2,812 shares of common stock acquired through a stock option exercise.

Key Highlights

  • Proposed sale: Mark Elliott Boulding, an officer of PTC Therapeutics, Inc., intends to sell 2,812 shares of common stock with an aggregate market value of $177,887.12.
  • Acquisition method: The 2,812 shares were acquired on November 16, 2026, via a stock option exercise from the issuer, with payment made in cash on the same date.
  • Broker: The sale is to be executed through Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield, RI 02917.
  • Shares outstanding: According to the filing, 83,544,284 shares of common stock were outstanding at the time of the notice.
  • Prior sales in past 3 months: Boulding sold a combined 5,078 shares across four transactions between August 17, 2026, and October 9, 2026, generating gross proceeds totaling $349,252.95.
  • Trading plan: The filing notes a Rule 10b5-1 plan adoption or instruction date of September 10, 2025.

Boulding's Proposed November 2026 Stock Sale at PTC Therapeutics

According to the Form 144 notice filed with the U.S. Securities and Exchange Commission on November 16, 2026, Mark Elliott Boulding, identified as an officer of PTC Therapeutics, Inc. (NASDAQ:PTCT), proposed to sell 2,812 shares of the company's common stock. The shares carry an aggregate market value of $177,887.12 as stated in the filing. The approximate date of sale listed is November 16, 2026, and the designated exchange is NASDAQ.

The filing discloses that the shares were acquired on November 16, 2026, through a stock option exercise from the issuer, with full cash payment made on the same date. PTC Therapeutics is headquartered at 500 Warren Corporate Center Drive, Warren, New Jersey 07059. The filing also references a Rule 10b5-1 written trading plan adopted or instruction given on September 10, 2025, under which the proposed transaction is said to be made.

The filing further reports four prior sales of common stock by Boulding within the preceding three months: 2,813 shares sold on August 17, 2026, for gross proceeds of $204,123.09; 1,638 shares sold on October 5, 2026, for $104,883.43; 435 shares sold on October 6, 2026, for $27,907.59; and 192 shares sold on October 9, 2026, for $12,338.84. The filing was signed by Gary Redman as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Mark Boulding.

What Was Disclosed

PTC Therapeutics officer Mark Elliott Boulding filed a Form 144 notice on November 16, 2026, disclosing a proposed sale of 2,812 common shares with an aggregate market value of $177,887.12, acquired through a stock option exercise and to be sold through Fidelity Brokerage Services LLC.